Skip to main content
PALISADE BIO, INC. logo

PALISADE BIO, INC. — Investor Relations & Filings

Ticker · PALI ISIN · US6963894026 LEI · 549300W6LIDX3I5XXT34 US Manufacturing
Filings indexed 1,045 across all filing types
Latest filing 2026-05-12 Registration Form
Country US United States of America
Listing US PALI

About PALISADE BIO, INC.

https://palisadebio.com/

Palisade Bio, Inc. is a clinical-stage biopharmaceutical company that develops and advances novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases. The company focuses on next-generation precision therapies, utilizing its phosphodiesterase-4 (PDE4) inhibitor prodrug platform. This platform is engineered to enable the targeted, oral delivery of therapeutics specifically to the gastrointestinal tract, aiming to enhance efficacy at the disease site while minimizing systemic side effects. Its lead development candidate, PALI-2108, is an oral PDE4 inhibitor prodrug being investigated for the treatment of inflammatory bowel diseases like ulcerative colitis.

Recent filings

Filing Released Lang Actions
S-3 - PALISADE BIO, INC. (0001357459) (Filer)
Registration Form
2026-05-12 English
10-Q - PALISADE BIO, INC. (0001357459) (Filer)
Interim / Quarterly Report
2026-05-12 English
ARS - PALISADE BIO, INC. (0001357459) (Filer)
Annual Report
2026-04-29 English
8-K - PALISADE BIO, INC. (0001357459) (Filer)
Regulatory Filings
2026-04-02 English
10-K - PALISADE BIO, INC. (0001357459) (Filer)
Annual Report FY 2025
2026-03-20 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.